Cargando…

Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer

Advances in the immunotherapy of cancer have prolonged survival for cancer patients, but the clinical and financial impact of treatments must be considered in determining the overall clinical utility and economic value of therapeutic agents. Quality-adjusted life years and incremental cost-effective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Peter Paul, Eton, Omar, Garrison, Louis P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724271/ https://www.ncbi.nlm.nih.gov/pubmed/31481112 http://dx.doi.org/10.1186/s40425-019-0707-9

Ejemplares similares

Antibiotic therapy and outcome from immune-checkpoint inhibitors
por: Pinato, David J., et al.
Publicado: (2019)

The gut microbiota and immune checkpoint inhibitors
por: Humphries, Audrey, et al.
Publicado: (2018)

Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies
por: Garrison, Louis P, et al.
Publicado: (2021)

Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors
por: Mundra, Vatsala, et al.
Publicado: (2023)

Challenges of predicting immune checkpoint therapy responders in lung cancer
por: Marwitz, Sebastian
Publicado: (2019)

Immune checkpoint inhibitor-related acral vasculitis
por: Comont, Thibault, et al.
Publicado: (2018)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity
por: Lee, Karla A, et al.
Publicado: (2020)

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology
por: Jardim, Denis L., et al.
Publicado: (2018)

COVID-19 and immune checkpoint inhibitors: initial considerations
por: Sullivan, Ryan J, et al.
Publicado: (2020)

Immune checkpoint inhibitors: here to stay
por: Carvalho, Filomena Marino, et al.
Publicado: (2023)

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
por: Akhuba, Liia, et al.
Publicado: (2023)

Considerations for Use of Immune Checkpoint Inhibitors in Cancer Therapy for Patients with Co-Existing Thyroid Eye Disease
por: Chau, Charlene Y. C., et al.
Publicado: (2020)

Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
por: Haratani, Koji, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
por: Belluomini, Lorenzo, et al.
Publicado: (2019)

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors
por: Bersanelli, Melissa
Publicado: (2020)

How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases?
por: Minami, Yasunori, et al.
Publicado: (2022)

Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatment
por: Nishino, Mizuki
Publicado: (2016)

The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung
por: Ichiki, Yoshinobu, et al.
Publicado: (2020)

Value Insider Season 1 Episode 5: What Other Aspects of Value May Be Relevant? (Societal Impact) [Podcast]
por: Garrison, Louis P, et al.
Publicado: (2022)

Immune checkpoint inhibitor induced neurocognitive deficits in patients
por: Zeiser, Robert, et al.
Publicado: (2023)

Increased abscopal responses after radiation therapy for oligoprogressive patients receiving immune checkpoint inhibitors?
por: Doyen, Jérôme, et al.
Publicado: (2023)

A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer
por: Antonarakis, Emmanuel S.
Publicado: (2019)

A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment
por: Rossi, Ernesto, et al.
Publicado: (2020)

Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology
por: Özdemir, Berna C
Publicado: (2021)

Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis
por: Xavier, Camila Bragança, et al.
Publicado: (2022)

Management of immune checkpoint therapy for patients with cancer in the face of COVID-19
por: Shen, Chen, et al.
Publicado: (2020)

Immune checkpoint inhibitor in liver cancer—unique regional differences
por: Obi, Shuntaro, et al.
Publicado: (2020)

Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
por: Ornstein, Moshe C., et al.
Publicado: (2023)

A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma
por: Fei, Kailun, et al.
Publicado: (2020)

Is there a role for stereotactic body radiation before immune checkpoint inhibitor therapy for advanced hepatocellular carcinoma?
por: Mukherjee, Sandeep
Publicado: (2023)

The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER)
por: Langley, Paul C
Publicado: (2020)

Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action
por: Neilan, Tomas G., et al.
Publicado: (2018)

Taking the bull by the horn: the frontline use of infliximab for the treatment of immune checkpoint inhibitor-induced enterocolitis
por: Esfahani, Khashayar
Publicado: (2018)

Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19
por: Gatto, Lidia, et al.
Publicado: (2020)

Consideration of Severe Coronavirus Disease 2019 As Viral Sepsis and Potential Use of Immune Checkpoint Inhibitors
por: Odabasi, Zekaver, et al.
Publicado: (2020)

Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
por: Zou, Xue-lin, et al.
Publicado: (2021)

Immune checkpoint inhibitors and the shared epitope theory: from hypothesis to practice
por: Lerrer, Shalom, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n0gfks7va0u49aqk9jcgugpa73